Macular Degeneration: National Seminar Series

Oct. 26, 2012 - PRLog -- The purpose of these programs is to provide local communities with an opportunity to learn about the latest advances in macular degeneration research, medications, therapies, nutrition, low vision and treatment in order to improve the quality of life of those affected by macular degeneration.

These events are designed to give an overview of age-related macular degeneration (AMD), including the progression of the disease and the dangers of vision loss as a result. These programs will also cover precautionary methods that may delay the onset of AMD and reduce retinal damage.

For more information about the national series or to learn if we’re coming to a city near you, please call (941) 893-4388; visit MDA online at www.maculardegenerationassociation.org, or email Danielle@maculardegenerationassociation.org

About the Macular Degeneration Association (MDA)

The Macular Degeneration Association is a nonprofit health organization dedicated to educating and empowering age-related macular degeneration patients all across the world. Age-related macular degeneration (AMD) is an increasingly prevalent degenerative eye disease, affecting millions of aging seniors. The mission of MDA is to educate patients on the latest advances in treating AMD. However, our focus extends far beyond diagnosed patients. We are committed to the senior population at large, those most at risk of developing macular degeneration.

Our goal is to provide information about risk factors, genetic predisposition, and proper diagnosis, as well as preventative efforts and treatment options that will likely reduce the most adverse effect of AMD, blindness. MDA is passionate about funding and developing sophisticated patient education and advocacy programs designed to improve macular patients’ quality of life. This is accomplished through the Association’s patient education conferences and seminars held nationwide.

The Association honors its commitment to prioritizing patient education by aligning itself with experts in the macular field, investigating retina-related scientific breakthroughs, and disseminating new scientific advances to macular patients across the world. We strongly believe that providing support, education and empowerment to the millions of people living with age-related macular degeneration will improve patient quality of life, and energize the retina field to develop advances in treating AMD.